Hikma Pharmaceuticals PLC stock (GB00B128J450): FTSE 100 drug maker trades steady after recent gains

Hikma Pharmaceuticals PLC shares on the London Stock Exchange traded broadly sideways on 06/03/2026, keeping the FTSE 100-listed generic and specialty drug producer in focus for investors following its year-to-date performance and stable fundamentals.

Hikma Pharmaceuticals PLC shares were little changed in London trading on 06/03/2026, with the FTSE 100 constituent moving broadly sideways after a period of recent gains that has taken the stock to around the mid-1,400 pence level on the London Stock Exchange.

The stock most recently changed hands at about 1,421 pence on the LSE under the ticker HIK as of 06/02/2026, close to quotes showing a sell price of 1,471.00 pence and a buy price of 1,472.00 pence in early June trading, according to AJ Bell data as of 06/03/2026.AJ Bell as of 06/03/2026

Measured from the start of the year, Hikma shares have eased from about 1,550 pence to roughly 1,421 pence, implying a decline of around 8.3% year-to-date as of 06/02/2026, according to MarketBeat figures.MarketBeat as of 06/02/2026

Hikma is headquartered in London in the United Kingdom and is primarily listed on the London Stock Exchange, making developments at the company closely watched by domestic UK equity investors who track the FTSE 100.

For investors in the euro area, the stock is also available via German trading venues, where Hikma can be traded in euros on platforms such as Tradegate in parallel with its home listing in London, although liquidity and pricing are typically anchored by the LSE quotation.

The stock traded at roughly 1,421 pence on 06/02/2026 on the London Stock Exchange, according to MarketBeat data, highlighting a relatively stable price pattern in the latest sessions even as the broader pharmaceuticals sector remains sensitive to regulatory news and pipeline developments.MarketBeat as of 06/02/2026

As of: 03.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Hikma
• Sector/industry: Pharmaceuticals and generics manufacturing
• Headquarters/country: London, United Kingdom
• Core markets: United States, Middle East and North Africa, Europe
• Key revenue drivers: Generic drugs, branded medicines, injectable pharmaceuticals
• Home exchange/listing venue: London Stock Exchange (HIK)
• Trading currency: GBP

Hikma Pharmaceuticals PLC: core business model

Hikma focuses on developing, manufacturing, and supplying a broad range of generic, branded, and injectable medicines across the United States, Europe, and emerging markets, with sales driven largely by its portfolio breadth in generics and sterile injectables as well as select branded therapies in the Middle East and North Africa.

Hikma Pharmaceuticals PLC in peer comparison

In the United Kingdom, Hikma is part of a group of large listed pharmaceutical names that includes AstraZeneca and GSK, although its focus on generics and injectables differentiates it from these larger research-based peers.MarketBeat as of 06/02/2026

According to MarketBeat competitor data as of 06/02/2026, Hikma trades around 1,421 pence, while AstraZeneca and GSK shares change hands at materially higher absolute price levels, reflecting their larger market capitalizations and originator-drug business models, whereas Hikma is positioned more squarely in the generics and specialty niche within the broader global pharmaceuticals landscape.MarketBeat as of 06/02/2026

Conclusion

Hikma Pharmaceuticals PLC shares traded broadly flat in early June London dealing, with the stock hovering around the mid-1,400 pence level after an 8.3% decline from the start of the year, according to MarketBeat data as of 06/02/2026.

In the wider pharmaceuticals space, Hikma occupies a distinct position versus larger UK-listed originator peers such as AstraZeneca and GSK, as it leans more heavily on generics and injectables, which can lead to different drivers for margins, competition, and pricing.

How investors weigh Hikma's valuation and prospects within the FTSE 100 and against other global drug makers will continue to depend on upcoming company news, regulatory developments, and sector dynamics across its key regions, particularly the United States and the Middle East and North Africa.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.